321 related articles for article (PubMed ID: 19952991)
1. Histology of fibrovascular membranes of proliferative diabetic retinopathy after intravitreal injection of bevacizumab.
Kubota T; Morita H; Tou N; Nitta N; Tawara A; Satoh H; Shimajiri S
Retina; 2010 Mar; 30(3):468-72. PubMed ID: 19952991
[TBL] [Abstract][Full Text] [Related]
2. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy.
Qian J; Lu Q; Tao Y; Jiang YR
Retina; 2011 Jan; 31(1):161-8. PubMed ID: 20890241
[TBL] [Abstract][Full Text] [Related]
3. Fibrous membranes in diabetic retinopathy and bevacizumab.
Pattwell DM; Stappler T; Sheridan C; Heimann H; Gibran SK; Wong D; Hiscott P
Retina; 2010; 30(7):1012-6. PubMed ID: 20616680
[TBL] [Abstract][Full Text] [Related]
4. Ghost cell glaucoma after intravitreal bevacizumab for postoperative vitreous hemorrhage following vitrectomy for proliferative diabetic retinopathy.
Liu L; Wu WC; Yeung L; Wang NK; Kuo YH; Chao AN; Chen KJ; Chen TL; Lai CC; Hwang YS; Chen YP
Ophthalmic Surg Lasers Imaging; 2010; 41(1):72-7. PubMed ID: 20128573
[TBL] [Abstract][Full Text] [Related]
5. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T
Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
[TBL] [Abstract][Full Text] [Related]
6. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment.
Oshima Y; Shima C; Wakabayashi T; Kusaka S; Shiraga F; Ohji M; Tano Y
Ophthalmology; 2009 May; 116(5):927-38. PubMed ID: 19269033
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial.
Ahmadieh H; Shoeibi N; Entezari M; Monshizadeh R
Ophthalmology; 2009 Oct; 116(10):1943-8. PubMed ID: 19699531
[TBL] [Abstract][Full Text] [Related]
8. Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: histopathologic findings and clinical implications.
El-Sabagh HA; Abdelghaffar W; Labib AM; Mateo C; Hashem TM; Al-Tamimi DM; Selim AA
Ophthalmology; 2011 Apr; 118(4):636-41. PubMed ID: 21055812
[TBL] [Abstract][Full Text] [Related]
9. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy.
Ishikawa K; Honda S; Tsukahara Y; Negi A
Eye (Lond); 2009 Jan; 23(1):108-11. PubMed ID: 17891057
[TBL] [Abstract][Full Text] [Related]
10. Altered vascular microenvironment by bevacizumab in diabetic fibrovascular membrane.
Nakao S; Ishikawa K; Yoshida S; Kohno R; Miyazaki M; Enaida H; Kono T; Ishibashi T
Retina; 2013 May; 33(5):957-63. PubMed ID: 23503340
[TBL] [Abstract][Full Text] [Related]
11. Clinical and histological findings after intravitreal injection of bevacizumab (Avastin) in a porcine model of choroidal neovascularization.
Lassota N; Prause JU; Scherfig E; Kiilgaard JF; la Cour M
Acta Ophthalmol; 2010 May; 88(3):300-8. PubMed ID: 19416113
[TBL] [Abstract][Full Text] [Related]
12. Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy.
Hattori T; Shimada H; Nakashizuka H; Mizutani Y; Mori R; Yuzawa M
Retina; 2010 May; 30(5):761-4. PubMed ID: 20453802
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy.
Sawada O; Kawamura H; Kakinoki M; Sawada T; Ohji M
Arch Ophthalmol; 2007 Oct; 125(10):1363-6. PubMed ID: 17923544
[TBL] [Abstract][Full Text] [Related]
14. Succinate increases in the vitreous fluid of patients with active proliferative diabetic retinopathy.
Matsumoto M; Suzuma K; Maki T; Kinoshita H; Tsuiki E; Fujikawa A; Kitaoka T
Am J Ophthalmol; 2012 May; 153(5):896-902.e1. PubMed ID: 22265145
[TBL] [Abstract][Full Text] [Related]
15. Histopathology of neovascular tissue from eyes with proliferative diabetic retinopathy after intravitreal bevacizumab injection.
Kohno R; Hata Y; Mochizuki Y; Arita R; Kawahara S; Kita T; Miyazaki M; Hisatomi T; Ikeda Y; Aiello LP; Ishibashi T
Am J Ophthalmol; 2010 Aug; 150(2):223-229.e1. PubMed ID: 20542485
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab.
Ma Y; Zhang Y; Zhao T; Jiang YR
Am J Ophthalmol; 2012 Feb; 153(2):307-313.e2. PubMed ID: 21982107
[TBL] [Abstract][Full Text] [Related]
17. Optic atrophy after anti-vascular endothelial growth factor injection in diabetic patients with proliferative diabetic retinopathy.
Singalavanija A; Hemarat K; Kedkovid N; Tanterdtham J; Namatra C; Trinavarat A; Rodanant N; Thoongsuwan S
J Med Assoc Thai; 2013 Mar; 96(3):318-23. PubMed ID: 23539935
[TBL] [Abstract][Full Text] [Related]
18. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy.
Arevalo JF; Maia M; Flynn HW; Saravia M; Avery RL; Wu L; Eid Farah M; Pieramici DJ; Berrocal MH; Sanchez JG
Br J Ophthalmol; 2008 Feb; 92(2):213-6. PubMed ID: 17965108
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy.
di Lauro R; De Ruggiero P; di Lauro R; di Lauro MT; Romano MR
Graefes Arch Clin Exp Ophthalmol; 2010 Jun; 248(6):785-91. PubMed ID: 20135139
[TBL] [Abstract][Full Text] [Related]
20. Repeated intravitreal bevacizumab (Avastin(®)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation.
Schmidinger G; Maar N; Bolz M; Scholda C; Schmidt-Erfurth U
Acta Ophthalmol; 2011 Feb; 89(1):76-81. PubMed ID: 21272288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
